IN VIVO TESTING OF A LEAD COQ10 BIOSYNTHESIS INHIBITOR IN AN SK-BR-3 XENOGRAPH MOUSE MODEL

在 SK-BR-3 异种小鼠模型中对先导 COQ10 生物合成抑制剂进行体内测试

• 批准号: 10953983
• 负责人: CHRISTOPHER DAMOCI
• 金额: $ 2.44万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-26 至 2024-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10953983
• 关键词: VIVO; TESTING; LEAD; COQ10; BIOSYNTHESIS

NCATS TDB has been collaborating with Dr Brent Stockwell’s group at Columbia Univ. to develop small molecules inhibitors of CoQ10 biosynthesis for the treatment of cancer. Currently, we have a series of inhibitors that show good potency and selectivity in vitro. We would like to test our lead inhibitor in a mouse model xenografted with SK-BR-3 human breast cancer cells. NCATS does not have in vivo efficacy testing facility nor capacity to run in vivo efficacy models, and therefore must get this service through a contractor.

NCATS TDB一直在与哥伦比亚大学的布伦特斯托克韦尔博士的小组合作，开发用于治疗癌症的辅酶Q10生物合成的小分子抑制剂。目前，我们有一系列的抑制剂，显示出良好的效力和选择性在体外。我们想在异种移植SK-BR-3人乳腺癌细胞的小鼠模型中测试我们的先导抑制剂。NCATS没有体内功效测试设施，也没有运行体内功效模型的能力，因此必须通过承包商获得这项服务。